

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.10 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and at the request of the Stock Exchange.

The board (the “**Board**”) of directors (“**Directors**”, and each a “**Director**”) of the Company was aware of recent unusual movements in the price and trading volume of the shares of the Company (the “**Shares**”) on the Stock Exchange. Having made such enquiries with respect to the Company as is reasonable in the circumstances, the Board confirms that, save as disclosed below, it is not aware of any reasons for these share price or trading volume movements, and it is not aware of any information which must be announced to avoid a false market in the Shares or of any inside information that needs to be disclosed pursuant to the Inside Information Provision (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

On October 10, 2022, the Investigational New Drug (“**IND**”) applications for the Company’s two self-developed anti-tumor drug candidates SIM0237 (anti-PD-L1/IL-15 bispecific antibody) and SIM0348 (TIGIT/PVRIG bispecific antibody) were accepted by the Center For Drug Evaluation (藥品審評中心), National Medical Products Administration (國家藥品監督管理局), but has yet to obtain the Clinical Trial Approvals.

This announcement is made by the order of the Company and each Director collectively and individually accepts responsibility for the accuracy of this announcement.

The Company cannot guarantee that SIM0237 and SIM0348 will be able to successfully obtain the Clinical Trial Approvals. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, October 20, 2022

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. TANG Renhong and Mr. WAN Yushan as the executive Directors; and Mr. SONG Ruilin, Mr. WANG Jianguo and Mr. WANG Xinhua as the independent non-executive Directors.